Kezar, lupus nephritis
Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug
According to the safety findings, four Grade Five serious adverse events were reported during the Phase II PALIZADE trial.
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment
William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.
Kezar halts dosing and enrollment in key lupus study after 4 patient deaths
Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary hold comes after Kezar restructured last year to in a bid to support its lupus and hepatitis candidate zetomipzomib.
Kezar Life Sciences pauses trial for lupus treatment after patient deaths
Kezar Life Sciences said on Monday it has paused a trial of its experimental drug for lupus to review safety data after four patients died in the mid-stage study. The San Francisco-based company said it had informed the U.
Setback for Kezar Life Sciences’ Lupus candidate zetomipzomib
Kezar Life Sciences saw its share tumble more than 42% to 40.77 yesterday, after it revealed it was voluntarily pausing enrollment of new patients and dosing of ongoing patients in the Phase IIb PALIZADE clinical trial,
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced the voluntary cessation in enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE clinical trial,
Medical firm pauses trial for lupus treatment after patient deaths in Philippines, Argentina
KEZAR Life Sciences said on Monday it has paused a trial of its experimental drug for lupus to review safety data after four patients died in the mid-stage study. The San Francisco-based company said it had informed the US Food and Drug Administration and European regulators of the decision to pause enrollment and dosing in
Kezar halts lupus nephritis trial on four fatalities
South San Francisco-based Kezar Life Sciences Inc. voluntarily stopped its phase IIb Palizade trial of zetomipzomib in active lupus nephritis, following four fatal, or grade 5, serious adverse events of patients enrolled in the Philippines and Argentina.
Kezar Life Sciences Halts Trial of Lupus-Nephritis Treatment After Deaths
Kezar Life Sciences said it voluntarily suspended enrollment and dosing in a clinical trial of a treatment for an autoimmune kidney disease after four patients died.
Kezar Life Sciences halts mid-stage trial for lupus treatment
Kezar Life Sciences said on Monday it has stopped enrollment of new patients and dosing of existing patients in its mid-stage study for treating a symptom of lupus, following an independent committee's recommendation after four deaths.
Maintaining Hold on Kezar Life Sciences Amid Safety Concerns and Financial Valuation
Wells Fargo analyst Derek Archila assigned a Hold rating on Kezar Life Sciences (KZR – Research Report) yesterday and set a price target ...
Renal & Urology News6h
Significant Benefit Seen With Obinutuzumab in Lupus Nephritis Trial
Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.
BioSpace4d
Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...